Dermira (DERM) Rating Increased to Hold at BidaskClub

Dermira (NASDAQ:DERM) was upgraded by equities researchers at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Saturday.

A number of other equities analysts have also commented on DERM. Zacks Investment Research raised Dermira from a “sell” rating to a “hold” rating in a research note on Thursday, August 17th. Mizuho reissued a “buy” rating and set a $43.00 price target (up from $40.00) on shares of Dermira in a research note on Thursday, September 7th. Needham & Company LLC reissued a “buy” rating and set a $46.00 price target on shares of Dermira in a research note on Sunday, September 17th. Cantor Fitzgerald reissued a “buy” rating and set a $45.00 price target on shares of Dermira in a research note on Tuesday, September 26th. Finally, Leerink Swann reissued an “outperform” rating and set a $41.00 price target (down from $47.00) on shares of Dermira in a research note on Tuesday, November 7th. Four analysts have rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. Dermira has an average rating of “Hold” and an average price target of $43.33.

Dermira (NASDAQ:DERM) opened at $25.55 on Friday. Dermira has a one year low of $21.35 and a one year high of $38.75. The company has a debt-to-equity ratio of 1.40, a current ratio of 4.68 and a quick ratio of 4.68.

In other news, CEO Thomas G. Wiggans sold 9,500 shares of the firm’s stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $27.51, for a total value of $261,345.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Eugene A. Bauer sold 7,500 shares of the firm’s stock in a transaction that occurred on Wednesday, October 11th. The shares were sold at an average price of $30.04, for a total value of $225,300.00. The disclosure for this sale can be found here. Insiders sold a total of 28,200 shares of company stock valued at $794,131 over the last ninety days. Corporate insiders own 13.30% of the company’s stock.

Large investors have recently bought and sold shares of the company. BNP Paribas Arbitrage SA lifted its stake in shares of Dermira by 2,220.7% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,154 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 3,975 shares during the last quarter. Quantbot Technologies LP lifted its stake in shares of Dermira by 75.4% in the 3rd quarter. Quantbot Technologies LP now owns 5,371 shares of the biopharmaceutical company’s stock valued at $145,000 after purchasing an additional 2,309 shares during the last quarter. SG Americas Securities LLC lifted its stake in shares of Dermira by 66.8% in the 2nd quarter. SG Americas Securities LLC now owns 5,503 shares of the biopharmaceutical company’s stock valued at $160,000 after purchasing an additional 2,203 shares during the last quarter. Legal & General Group Plc lifted its stake in shares of Dermira by 16.3% in the 1st quarter. Legal & General Group Plc now owns 6,861 shares of the biopharmaceutical company’s stock valued at $236,000 after purchasing an additional 963 shares during the last quarter. Finally, Ardsley Advisory Partners bought a new stake in shares of Dermira in the 2nd quarter valued at approximately $291,000. 99.54% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Dermira (DERM) Rating Increased to Hold at BidaskClub” was originally published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.com-unik.info/2017/12/04/dermira-derm-rating-increased-to-hold-at-bidaskclub.html.

About Dermira

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Analyst Recommendations for Dermira (NASDAQ:DERM)

What are top analysts saying about Dermira Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Dermira Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit